Journal of Clinical Psychopharmacology最新文献

筛选
英文 中文
Progress on Pharmacogenetic Tests for Antidepressant Drug Selection Requires Properly Designed Studies. 抗抑郁药物选择的药物遗传学试验的进展需要适当设计的研究。
IF 2.9 3区 医学
Journal of Clinical Psychopharmacology Pub Date : 2026-07-01 Epub Date: 2026-05-25 DOI: 10.1097/JCP.0000000000002199
Bruce M Cohen, Leslie Citrome, Joseph F Goldberg, Matthew L Baum, Charles B Nemeroff
{"title":"Progress on Pharmacogenetic Tests for Antidepressant Drug Selection Requires Properly Designed Studies.","authors":"Bruce M Cohen, Leslie Citrome, Joseph F Goldberg, Matthew L Baum, Charles B Nemeroff","doi":"10.1097/JCP.0000000000002199","DOIUrl":"10.1097/JCP.0000000000002199","url":null,"abstract":"","PeriodicalId":15455,"journal":{"name":"Journal of Clinical Psychopharmacology","volume":" ","pages":"507-510"},"PeriodicalIF":2.9,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148149733","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Serotonin Syndrome Associated With Polypharmacy in an Elderly Patient With Dementia and Parkinson Disease. 老年痴呆和帕金森病患者血清素综合征与多药相关
IF 2.9 3区 医学
Journal of Clinical Psychopharmacology Pub Date : 2026-07-01 Epub Date: 2026-03-25 DOI: 10.1097/JCP.0000000000002170
Ahmet Torun, Nesibe Boyraz, Furkan Toksoy, Burç Çağrı Poyraz
{"title":"Serotonin Syndrome Associated With Polypharmacy in an Elderly Patient With Dementia and Parkinson Disease.","authors":"Ahmet Torun, Nesibe Boyraz, Furkan Toksoy, Burç Çağrı Poyraz","doi":"10.1097/JCP.0000000000002170","DOIUrl":"10.1097/JCP.0000000000002170","url":null,"abstract":"","PeriodicalId":15455,"journal":{"name":"Journal of Clinical Psychopharmacology","volume":"46 4","pages":"490-492"},"PeriodicalIF":2.9,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148308320","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Journal of Clinical Psychopharmacology Updates. 临床精神药理学杂志。
IF 2.9 3区 医学
Journal of Clinical Psychopharmacology Pub Date : 2026-07-01 Epub Date: 2026-06-04 DOI: 10.1097/JCP.0000000000002201
Anthony J Rothschild
{"title":"Journal of Clinical Psychopharmacology Updates.","authors":"Anthony J Rothschild","doi":"10.1097/JCP.0000000000002201","DOIUrl":"10.1097/JCP.0000000000002201","url":null,"abstract":"","PeriodicalId":15455,"journal":{"name":"Journal of Clinical Psychopharmacology","volume":" ","pages":"373"},"PeriodicalIF":2.9,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148163421","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The Cardiac Safety of High-Dose Propranolol Used to Treat Severe Behaviors With Autism Spectrum Disorders. 大剂量心得安治疗自闭症谱系障碍严重行为的心脏安全性。
IF 2.9 3区 医学
Journal of Clinical Psychopharmacology Pub Date : 2026-07-01 Epub Date: 2026-06-02 DOI: 10.1097/JCP.0000000000002155
Kristen A Moody, Eric D Fethke, Phillip Wilken, Eric B London
{"title":"The Cardiac Safety of High-Dose Propranolol Used to Treat Severe Behaviors With Autism Spectrum Disorders.","authors":"Kristen A Moody, Eric D Fethke, Phillip Wilken, Eric B London","doi":"10.1097/JCP.0000000000002155","DOIUrl":"https://doi.org/10.1097/JCP.0000000000002155","url":null,"abstract":"<p><strong>Background: </strong>Aggression and self-abusive behaviors are serious problems in the developmentally disabled. Several medications have shown efficacy, but many individuals remain inadequately treated or intolerant of the side effects of various medications. High-dose propranolol has been shown to be effective for some individuals with various diagnoses. Clinicians' use of high-dose propranolol has been limited by a lack of evidence of cardiac safety. We are presenting a retrospective review of the cardiologic workup of 52 cases of the use of high-dose propranolol for individuals with autism spectrum and related disorders.</p><p><strong>Procedures: </strong>We report the results of electrocardiogram, Holter monitor, blood pressure, heart rate, and echocardiography in this cohort who were on doses of propranolol up to 1200 mg per day with a mean dose of 496.6 mg per day. The ages ranged from 12 to 49 years with a mean of 21.6 years.</p><p><strong>Results: </strong>Clinically, there were no serious adverse events over the 8 years of accumulated data on this cohort. Three of the 52 cases were discontinued from propranolol due to side effects of bradycardia and or hypotension. There were no adverse effects noted on the Holter monitor or the echocardiography. There was a correlation between heart rate and blood pressure, but for the vast majority, these were not clinically significant.</p><p><strong>Conclusions: </strong>In our population, high-dose propranolol appeared to be safe from a cardiologic perspective. Our population skewed toward young individuals without preexisting heart pathology. We recommend its use with appropriate caution for any given individual.</p>","PeriodicalId":15455,"journal":{"name":"Journal of Clinical Psychopharmacology","volume":"46 4","pages":"399-403"},"PeriodicalIF":2.9,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148308241","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Reply to "Progress on Pharmacogenetic Tests for Antidepressant Drug Selection Requires Properly Designed Studies". 抗抑郁药物选择的药物遗传学试验的进展需要适当设计的研究。
IF 2.9 3区 医学
Journal of Clinical Psychopharmacology Pub Date : 2026-07-01 Epub Date: 2026-06-02 DOI: 10.1097/JCP.0000000000002189
Renee E Albers, Alexander Gutin, Boadie W Dunlop
{"title":"Reply to \"Progress on Pharmacogenetic Tests for Antidepressant Drug Selection Requires Properly Designed Studies\".","authors":"Renee E Albers, Alexander Gutin, Boadie W Dunlop","doi":"10.1097/JCP.0000000000002189","DOIUrl":"10.1097/JCP.0000000000002189","url":null,"abstract":"","PeriodicalId":15455,"journal":{"name":"Journal of Clinical Psychopharmacology","volume":" ","pages":"510-514"},"PeriodicalIF":2.9,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148149758","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Malignant Catatonia and Neuroleptic Malignant Syndrome Overlap in the Emergency Department: Diagnostic Challenges and Psychopharmacology Considerations. 恶性紧张症和抗精神病药恶性综合征在急诊科重叠:诊断挑战和精神药理学考虑。
IF 2.9 3区 医学
Journal of Clinical Psychopharmacology Pub Date : 2026-07-01 Epub Date: 2026-03-23 DOI: 10.1097/JCP.0000000000002172
Samyukta Girish Menon, Yulia Furlong
{"title":"Malignant Catatonia and Neuroleptic Malignant Syndrome Overlap in the Emergency Department: Diagnostic Challenges and Psychopharmacology Considerations.","authors":"Samyukta Girish Menon, Yulia Furlong","doi":"10.1097/JCP.0000000000002172","DOIUrl":"10.1097/JCP.0000000000002172","url":null,"abstract":"","PeriodicalId":15455,"journal":{"name":"Journal of Clinical Psychopharmacology","volume":" ","pages":"496-498"},"PeriodicalIF":2.9,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147499292","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The Need to Revise the Paliperidone Palmitate Loading Dose Strategy: Toward Personalized Medicine to Enhance Patient Safety. 修订棕榈酸帕利哌酮负荷剂量策略的必要性:面向个性化医疗以提高患者安全。
IF 2.9 3区 医学
Journal of Clinical Psychopharmacology Pub Date : 2026-07-01 Epub Date: 2026-04-10 DOI: 10.1097/JCP.0000000000002186
Sheldon H Preskorn, Vy Le
{"title":"The Need to Revise the Paliperidone Palmitate Loading Dose Strategy: Toward Personalized Medicine to Enhance Patient Safety.","authors":"Sheldon H Preskorn, Vy Le","doi":"10.1097/JCP.0000000000002186","DOIUrl":"10.1097/JCP.0000000000002186","url":null,"abstract":"","PeriodicalId":15455,"journal":{"name":"Journal of Clinical Psychopharmacology","volume":" ","pages":"369-371"},"PeriodicalIF":2.9,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147645579","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A Pilot, Dose-Finding, Pharmacodynamic and Pharmacokinetic Study of Orally Administered Botanical Kratom. 口服植物克拉通的先导、剂量测定、药效学和药代动力学研究。
IF 2.9 3区 医学
Journal of Clinical Psychopharmacology Pub Date : 2026-07-01 Epub Date: 2026-03-16 DOI: 10.1097/JCP.0000000000002158
Chad J Reissig, Ling Chen, Srikanth C Nallani, E Gregory Hawkins, Steven Galati, Katherine Bonson, Siva Rama Raju Kanumuri, Christopher R McCurdy, Abhisheak Sharma, Beatrice Setnik, Denise Milovan, Debra Kelsh, Dominic Chiapperino
{"title":"A Pilot, Dose-Finding, Pharmacodynamic and Pharmacokinetic Study of Orally Administered Botanical Kratom.","authors":"Chad J Reissig, Ling Chen, Srikanth C Nallani, E Gregory Hawkins, Steven Galati, Katherine Bonson, Siva Rama Raju Kanumuri, Christopher R McCurdy, Abhisheak Sharma, Beatrice Setnik, Denise Milovan, Debra Kelsh, Dominic Chiapperino","doi":"10.1097/JCP.0000000000002158","DOIUrl":"10.1097/JCP.0000000000002158","url":null,"abstract":"<p><strong>Background: </strong>Kratom ( Mitragyna speciosa ) is a plant indigenous to Southeast Asia. This pilot study evaluated the pharmacodynamic (PD) effects, safety, and pharmacokinetics (PK) of kratom and several of its alkaloids.</p><p><strong>Methods: </strong>Recreational polydrug users (8 participants/cohort; 6 active: 2 placebo, N=40) completed the study. Participants had experience with opioids but were otherwise healthy. This study utilized a double-blind, between-subjects design where participants randomly received a single dose of placebo or kratom. The kratom used in the study had alkaloid levels representative of botanical kratom products (i.e., leaf) previously characterized in the literature and contained trace levels of 7-hydroxymitragynine (7-OH). The starting dose was 1 g and doses of 3, 8, 10, and 12 g were administered after safety reviews after each dose. After dosing, pupillometry and assessments of subjective effects were performed, and blood samples were collected. Safety assessments included adverse events (AE) monitoring, laboratory tests, vital signs, ECG assessments, physical examination findings, and assessment of suicidality.</p><p><strong>Results: </strong>No deaths or serious adverse events (SAEs) occurred. Somnolence, vomiting, and nausea were the most common AEs reported. Kratom alkaloid concentrations showed generally orderly, dose-related effects. At doses ≥3 g, kratom produced pupillary constriction. Few dose-related effects were observed, although the 12 g dose of kratom produced increases on several subjective measures including ratings of \"drug liking.\"</p><p><strong>Conclusions: </strong>This study investigated the safety of single-sourced botanical kratom; the results may not be representative of other kratom-containing products. Kratom produced some opioid-like effects including pupillary constriction, and the 12 g dose produced effects commonly associated with drugs of abuse such as visual analog scale (VAS) ratings of drug liking, good effects, and high.</p>","PeriodicalId":15455,"journal":{"name":"Journal of Clinical Psychopharmacology","volume":" ","pages":"386-398"},"PeriodicalIF":2.9,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147468144","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Pharmacological Treatment and Cognition in Bipolar I Disorder: Evidence From a Prospective Study in India. 双相I型障碍的药物治疗和认知:来自印度前瞻性研究的证据。
IF 2.9 3区 医学
Journal of Clinical Psychopharmacology Pub Date : 2026-07-01 Epub Date: 2026-03-13 DOI: 10.1097/JCP.0000000000002162
Bhavya Bhavya, Ajay Kumar Shukla, Abhijit Rozatkar, Shubham Atal
{"title":"Pharmacological Treatment and Cognition in Bipolar I Disorder: Evidence From a Prospective Study in India.","authors":"Bhavya Bhavya, Ajay Kumar Shukla, Abhijit Rozatkar, Shubham Atal","doi":"10.1097/JCP.0000000000002162","DOIUrl":"10.1097/JCP.0000000000002162","url":null,"abstract":"<p><strong>Background: </strong>Bipolar I disorder is frequently accompanied by persistent cognitive dysfunction, but the extent to which routine pharmacological treatment influences subjective and objective cognition remains unclear. We sought to examine short-term changes in cognitive functioning among euthymic bipolar I disorder patients receiving routine pharmacotherapy.</p><p><strong>Methods: </strong>In this prospective observational study, adults with bipolar I disorder in euthymia (Young Mania Rating Scale ≤10; Hamilton Depression Rating Scale ≤7) underwent cognitive assessment using the Cognitive Complaints in Bipolar Disorder Rating Assessment (COBRA) and the Montreal Cognitive Assessment (MoCA) at baseline and again after 3 to 4 months. Medication regimens, dose stability, adherence, and clinical variables were recorded. Paired tests evaluated within-subject cognitive change; categorical shifts were examined using the McNemar test. Limitations related to study design were explicitly evaluated.</p><p><strong>Results: </strong>Fifty-one participants were enrolled (median age 39 years), and 50 completed follow-up. COBRA scores improved from 7.48±7.13 to 4.04±5.94 (mean change -3.44; P <0.001), and MoCA scores increased from 23.90±4.89 to 25.84±4.40 (mean change +1.94; P <0.001). The proportion with normal cognition increased from 42% to 78% on MoCA, while COBRA-defined impairment decreased from 20% to 6%. Improvements were observed across medication classes, and no regimen demonstrated consistent superiority.</p><p><strong>Conclusions: </strong>Routine pharmacological treatment was associated with short-term cognitive improvement, but the findings are preliminary and not causal.</p>","PeriodicalId":15455,"journal":{"name":"Journal of Clinical Psychopharmacology","volume":" ","pages":"420-426"},"PeriodicalIF":2.9,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147443857","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Salute to Our Reviewers. 向我们的审稿人致敬。
IF 2.9 3区 医学
Journal of Clinical Psychopharmacology Pub Date : 2026-07-01 Epub Date: 2026-06-08 DOI: 10.1097/JCP.0000000000002200
{"title":"Salute to Our Reviewers.","authors":"","doi":"10.1097/JCP.0000000000002200","DOIUrl":"https://doi.org/10.1097/JCP.0000000000002200","url":null,"abstract":"","PeriodicalId":15455,"journal":{"name":"Journal of Clinical Psychopharmacology","volume":"46 4","pages":"518-519"},"PeriodicalIF":2.9,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148368564","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书